C4 Therapeutics, Inc. Stock Price, News & Analysis

C4 Therapeutics (NASDAQ:CCCC) reported Q2 2025 financial results and business updates, highlighting progress in its targeted protein degradation pipeline. The company's lead drug cemsidomide demonstrated promising Phase 1 results with 40% overall response rate (ORR) at 75 µg dose and 50% ORR at 100 µg dose in multiple myeloma patients.

Financial results showed revenue of $6.5M (down from $12.0M in Q2 2024), with a net loss of $26.0M. The company maintains a strong financial position with $223.0M in cash, extending runway to mid-2027. A milestone payment of $1M was earned from the Merck KGaA collaboration focused on KRAS family projects.

Following a productive FDA Type C meeting, C4T plans to initiate registrational development of cemsidomide in early 2026, focusing on multiple myeloma over non-Hodgkin's lymphoma for strategic reasons.

C4 Therapeutics (NASDAQ: CCCC) reported Q1 2025 financial results and key developments. The company's lead drug cemsidomide showed promising results in multiple myeloma treatment, achieving a 50% overall response rate at 100 µg dose and 40% ORR at 75 µg dose. Notably, one patient achieved minimal residual disease negative complete response. The company has completed Phase 1 dose escalation for multiple myeloma and expects FDA feedback by mid-2025. C4T reported $234.7 million in cash and equivalents, providing runway into 2027. Q1 2025 revenue was $7.2 million, up from $3.0 million in Q1 2024, while net loss decreased to $26.3 million ($0.37 per share) from $28.4 million. The company is prioritizing cemsidomide development while seeking partnership opportunities for its BRAF program.

C4 Therapeutics (CCCC) reported its Q4 and full year 2024 financial results, highlighting progress in its degrader portfolio. The company ended 2024 with $267.3 million in cash, providing runway into 2027.

Key clinical developments include cemsidomide showing a 36% overall response rate in Multiple Myeloma and 38% across NHL subtypes. In PTCL, cemsidomide achieved a 44% overall response rate. Clinical trials for both indications are expected to initiate in early 2026.

Financial highlights for 2024 include revenue of $35.6 million, up from $20.8 million in 2023. R&D expenses decreased to $110.6 million from $117.7 million, while G&A expenses remained flat at $42.1 million. Net loss improved to $105.3 million ($1.52 per share) compared to $132.5 million ($2.67 per share) in 2023.

C4 Therapeutics (Nasdaq: CCCC), a clinical-stage biopharmaceutical company focused on targeted protein degradation science, has announced its participation in two major investor conferences in March 2025.

The company will present at the TD Cowen 45th Annual Healthcare Conference on March 3rd at 9:10 am ET in Boston, MA. A live webcast will be accessible through the company's website's Events & Presentations page, with replay available for approximately 30 days after the event.

Additionally, management will attend the Leerink Partners Global Healthcare Conference on March 9th in Miami, FL.

C4 Therapeutics (CCCC) announced its 2025 milestones for its clinical portfolio of degrader medicines in oncology. The company highlighted progress across three main programs: cemsidomide for multiple myeloma and non-Hodgkin's lymphoma, CFT1946 for BRAF V600X solid tumors, and CFT8919 for non-small cell lung cancer.

Key developments include cemsidomide's promising data presented at ASH, showing a 36% overall response rate in multiple myeloma and 38% in non-Hodgkin's lymphoma. CFT1946's Phase 1 monotherapy dose escalation is expected to complete in H1 2025, with data in melanoma and colorectal cancer expected in H2 2025. The company's cash runway is expected to fund operations into 2027.

The company plans to initiate new clinical studies for cemsidomide in early 2026, including combinations with other agents for multiple myeloma and monotherapy for peripheral T-cell lymphoma. Data from CFT8919's Phase 1 study in Greater China will inform future development plans.

C4 Therapeutics (Nasdaq: CCCC), a clinical-stage biopharmaceutical company focused on targeted protein degradation science, has announced its participation in the 43rd Annual J.P. Morgan Healthcare Conference. Andrew Hirsch, the company's president and CEO, will deliver a presentation on Wednesday, January 15, 2025, at 2:15 PM PST (5:15 PM EST).

The presentation will be accessible via live webcast through C4T's website in the Events & Presentations section. Interested parties who cannot attend the live session can access a replay of the webcast, which will remain available on the company's website for a minimum of two weeks following the presentation.

C4 Therapeutics (CCCC) presented Phase 1 trial data for cemsidomide at the ASH Annual Meeting, showing promising results in both multiple myeloma (MM) and non-Hodgkin's lymphoma (NHL). In MM, cemsidomide with dexamethasone achieved a 36% overall response rate and 45% clinical benefit rate at the highest dose level. The drug demonstrated a well-tolerated safety profile with manageable neutropenia.

In NHL, cemsidomide monotherapy showed a 38% overall response rate and 19% complete metabolic response rate. Notably, in peripheral T-cell lymphoma, the drug achieved a 44% overall response rate and 25% complete metabolic response rate. The company is positioning cemsidomide for future development in multiple myeloma combination regimens and various NHL subtypes.

C4 Therapeutics (Nasdaq: CCCC) has appointed Steve Hoerter to its Board of Directors. Hoerter brings over 30 years of oncology commercialization and leadership experience, most recently serving as president and CEO of Deciphera Pharmaceuticals, which was acquired by ONO Pharmaceutical for $2.4 billion in June 2024. At Deciphera, he led the successful approval and launch of QINLOCK® for gastrointestinal stromal tumors. His previous roles include chief commercial officer at Agios Pharmaceuticals, where he oversaw the launches of TIBSOVO® and IDHIFA® for acute myeloid leukemia.

C4 Therapeutics (Nasdaq: CCCC) announced that its partner Betta Pharmaceuticals has dosed the first patient in a Phase 1 clinical trial of CFT8919 in Greater China. CFT8919 is an orally bioavailable allosteric degrader targeting EGFR L858R mutations in non-small cell lung cancer (NSCLC). The drug aims to overcome limitations of current EGFR tyrosine kinase inhibitors, particularly for patients with the L858R mutation. In China, where approximately 693,000 NSCLC cases are diagnosed annually, about 50% have EGFR mutations, with L858R being present in roughly 40% of EGFR-mutated cases. The collaboration with Betta Pharmaceuticals could yield up to $357 million in milestones plus royalties for C4T.